Genmab A/S GMAB 價格預測與預測

Q: 技術分析指標如何適用於 GMAB？

根據技術分析，Genmab A/S 的綜合信號為 Buy。Genmab A/S 有 3 個買入信號，2 個中性信號和 2 個賣出信號。

Q: GMAB 的費波那契回檔水準是多少？

Genmab A/S 的費波那契回檔水準是 介於 78.6% 和 100% 之間。

Q: Genmab A/S 的 RSI 是多少？

Genmab A/S 的 RSI 目前為 35.18，表明處於 中立 狀態

Q: Genmab A/S 接下來 12 個月的價格是多少？

Genmab A/S GMAB 接下來 12 個月的價格預估為 $28.4。

Q: Genmab A/S 預計會漲到多高？

據華爾街分析師稱，Genmab A/S 預計將達到 $182.9 的高預測值。

首頁

股票

GMAB

預測

GMAB 股票價格預測

Genmab A/S

$33.07

5.56%

$1.74

截至今日：Jan 21, 15:37:37 GMT-5

概觀預測收益股利財務狀況

關鍵數據

前收市價

$31.33

開盤價

$31.76

當日範圍

$31.73 - $33.23

52週區間

$17.23 - $35.43

交易量

1.4M

平均成交量

1.8M

每股盈餘 (TTM)

2.29

股息收益率

市值

$20.3B

什麼是 Genmab A/S？

Genmab A/S is an international biotechnology company, which engages in the development of human antibody therapeutics for the treatment of cancer and other diseases. The company specializes in the creation and development of antibody therapeutics for the treatment of cancer. The firm is the creator of the approved antibodies: DARZALEX (daratumumab) for the treatment of certain multiple myeloma indications, Kesimpta for the treatment of adults with relapsing forms of multiple sclerosis, TEPEZZA (teprotumumab) for the treatment of thyroid eye disease and FASPRO, for the treatment of adult patients with certain multiple myeloma indications. The first approved Genmab created therapy Arzerra, approved for the treatment of certain chronic lymphocytic leukemia indications, is available in Japan and is also available in other territories via compassionate use or oncology access programs. Genmab develops a broad clinical and pre-clinical product pipeline, and owns four antibody technologies, DuoBody bispecific platform, HexaBody platform, DuoHexaBody platform & HexElect platform.

功能特性

交易策略

資源

市場

Utilizing our sophisticated predictive model, we anticipate notable price fluctuations for GMAB in the upcoming periods. Looking toward the future, our 2027 projection indicates an average price target of $28.4. The lowest target is $-146.6338 and the highest is $182.9. Empower your investment choices with our cutting-edge, data-driven analysis!

GMAB 股價預測摘要

GMAB 的頂級分析師評級

根據 26 位分析師對 GMAB 的股票評級，更新於 Nov 01, 2025

Buy

Strong buy

Buy

Hold

Sell

Strong sell

Leveraging in-depth analyst evaluations, we have synthesized key insights from expert assessments to present a positive outlook for GMAB. Analysts highlight solid fundamentals and favorable market sentiment, suggesting upside potential in the near term. Based on this thorough expert analysis, we maintain an optimistic view of this stock. Our conclusion: GMAB is a Buy candidate.

GMAB stock price ended at $31.33 on 星期二, after dropping 2.85%

On the latest trading day Jan 20, 2026, the stock price of GMAB fell by 2.85%, dropping from $31.38 to $31.33. During the session, the stock saw a volatility of 2.13%, with prices oscillating between a daily low of $31.04 and a high of $31.70. On the latest trading day, the trading volume for GMAB decreased by 3.4M shares, aligning with the declining prices, which may indicate weakening market confidence in the near term. In total, 2.7M shares were traded, with a market value of approximately $19.2B.

GMAB 技術面訊號

技術面訊號摘要

購買訊號 3

中性訊號 2

賣出訊號 2

Strong Sell

Sell

Neutral

Buy

Strong Buy

GMAB 目前顯示 3 個買入訊號與 2 個賣出訊號。該股票自 12:00 AM 以來一直處於下跌趨勢狀態，在此期間價格總共變動了 -11.35%。整體而言，技術指標顯示中期後市趨勢為 Buy。

GMAB 的看漲／看跌訊號

我們的演算法透過分析移動平均線、RSI、MACD 和成交量等關鍵指標，為GMAB生成看漲和看跌訊號。這些見解可助您做出明智的投資決策。

後續問題

技術分析指標如何適用於 GMAB？



GMAB 的費波那契回檔水準是多少？



Genmab A/S 的 RSI 是多少？



Genmab A/S 接下來 12 個月的價格是多少？



Genmab A/S 預計會漲到多高？



Genmab A/S（GMAB）價格

GMAB 股價走勢圖